EP Patent

EP1838311A1 — G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes

Assigned to Prosidion Ltd · Expires 2007-10-03 · 19y expired

What this patent protects

Compounds of formula (I), or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

USPTO Abstract

Compounds of formula (I), or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

Drugs covered by this patent

Patent Metadata

Patent number
EP1838311A1
Jurisdiction
EP
Classification
—
Expires
2007-10-03
Drug substance claim
No
Drug product claim
No
Assignee
Prosidion Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.